Pharmaceutical

Nestlé divests peanut allergy treatment Palforzia to Stallergenes Greer

Nestlé has sold its peanut allergy drug Palforzia to Swiss biopharma Stallergenes Greer harma, concluding a year-long strategic review.

Sep 5, 2023 - 20:00
Nestlé divests peanut allergy treatment Palforzia to Stallergenes Greer
Nestlé has sold its peanut allergy drug Palforzia to Swiss biopharma Stallergenes Greer harma, concluding a year-long strategic review.
Read the original article

Tags:

Previous Article

STAT+: Lawmakers call on FDA to issue stricter bone graft guidance

Next Article

Direct oral anticoagulants’ positive effects on cancer-associated VTE

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: From a small town in Wales, a scientific sleuth has shaken Dana-Farber — and elevated the issue of research integrity

STAT+: From a small town in Wales, a scientific sleuth ...

Jan 28, 2024

STAT+: Pharmalittle: Deadline looms for drugmakers to negotiate with Medicare; GOP senator probes 340B program at two hospitals

STAT+: Pharmalittle: Deadline looms for drugmakers to n...

Sep 30, 2023

STAT+: Sanders, other lawmakers open probe into asthma inhaler makers over pricing, patent maneuvers

STAT+: Sanders, other lawmakers open probe into asthma ...

Jan 8, 2024